Evidence map›Paper›PMID 37457718›Full record

ReviewFrontiers in immunology2023

Role of exosomes in the development of the immune microenvironment in hepatocellular carcinoma.

Tanghua Li, Jiapeng Jiao, Haoteng Ke, Wenshan Ouyang, Luobin Wang, Jin Pan, Xin Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Tanghua LiThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Jiapeng JiaoThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Haoteng KeThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Wenshan OuyangThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Luobin WangThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Jin PanThe Department of Electronic Engineering, The Chinese University of Hong Kong, Hongkong, Hongkong SAR, China.
Xin LiZhujiang Hospital, Southern Medical University, Guangzhou, China.
Southern Medical University · CNChinese University of Hong Kong · HKZhujiang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite numerous improved treatment methods used in recent years, hepatocellular carcinoma (HCC) is still a disease with a high mortality rate. Many recent studies have shown that immunotherapy has great potential for cancer treatment. Exosomes play a significant role in negatively regulating the immune system in HCC. Understanding how these exosomes play a role in innate and adaptive immunity in HCC can significantly improve the immunotherapeutic effects on HCC. Further, engineered exosomes can deliver different drugs and RNA molecules to regulate the immune microenvironment of HCC by regulating the aforementioned immune pathway, thereby significantly improving the mortality rate of HCC. This study aimed to declare the role of exosomes in the development of the immune microenvironment in HCC and list engineered exosomes that could be used for clinical transformation therapy. These findings might be beneficial for clinical patients.

Indexed as

Carcinoma, HepatocellularExosomesLiver NeoplasmsHumansImmunotherapyTumor Microenvironmentengineered exosomeexosomehepatocellular carcinomaimmunotherapytumor immune microenvironment

Identifiers

PMID37457718
PMCPMC10339802
OpenAlexW4382538553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.